NRIX
Nurix Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 3
Sell signal 2
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NRIX
Nurix Therapeutics, Inc.
A clinical-stage biopharmaceutical company that develops targeted protein modulation drugs
1700 Owens Street, Suite 205, San Francisco, CA 94158
--
Nurix Therapeutics, Inc., was incorporated in Delaware on August 27, 2009. The Company is a biopharmaceutical company focused on the discovery, development and commercialization of oral small molecule therapies designed to regulate cellular protein levels as new treatments for cancer and immune disorders. Leveraging their extensive expertise in E3 ligases and their proprietary DNA coding library, the company has established an integrated discovery platform, DELigase, to identify and develop new drug candidates for E3 ligases.
Company Financials
EPS
NRIX has released its 2025 Q2 earnings. EPS was reported at -0.52, versus the expected -0.74, beating expectations. The chart below visualizes how NRIX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
NRIX has released its 2025 Q2 earnings report, with revenue of 44.06M, reflecting a YoY change of 264.34%, and net profit of -43.46M, showing a YoY change of 2.43%. The Sankey diagram below clearly presents NRIX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
